First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gregory M. Glenn, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Gale Smith, Nita Patel, Matthew B. Frieman, Robert E. Haupt, James Logue, Marisa McGrath, Stuart Weston, Pedro A. Piedra, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Jason D. Lickliter, Paul Griffin, Bethanie Wilkinson
doi: https://doi.org/10.1101/2020.08.05.20168435

Data Availability

These are interim data, and individual participants remain masked to individual vaccine assignment. Therefore, it would be inappropriate to share individual level results at this time.

Back to top
Posted August 06, 2020.
Download PDF

Supplementary Material

Data/Code
Email
First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech, Gregory M. Glenn, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Gale Smith, Nita Patel, Matthew B. Frieman, Robert E. Haupt, James Logue, Marisa McGrath, Stuart Weston, Pedro A. Piedra, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Jason D. Lickliter, Paul Griffin, Bethanie Wilkinson
medRxiv 2020.08.05.20168435; doi: https://doi.org/10.1101/2020.08.05.20168435
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area